Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

Eye on Pharma: Coherus Offloads Cimerli; Celltrion Files for CT-P47; Alvotech Shares Denosumab Results

January 30th 2024

By Skylar Jeremias

Article

Coherus Biosciences has sold its ranibizumab biosimilar (Cimerli) to Sandoz; Celltrion has completed its biologics license application filing for its tocilizumab biosimilar (CT-P47); Alvotech shares positive pharmacokinetic results for its denosumab biosimilar candidate.

What Types of Patents Are to Blame for Biosimilar Market Delays?

January 29th 2024

By Skylar Jeremias

Article

Although manufacturing patents tend to be the most common type of patent referenced in litigation regarding biosimilar development, other patents actually have a greater impact on delays for biosimilar market launches.

Biosimilar Adoption Policy Proves Successful After 8 Years in a UK Tertiary Hospital

January 28th 2024

By Skylar Jeremias

Article

During a 6-year follow-up period, a UK tertiary hospital observed greater biosimilar adoption than the English average after it implemented a new policy that prioritizes best-value biologics, including biosimilars, for new-start patients and those already treated with originators.

Biosimilars Improve Access to Biologic Therapies, JAK Inhibitors for Patients With RMDs

January 26th 2024

By Cameron Santoro

Article

A 10-year analysis in Poland found that the introduction of biosimilar drugs significantly increased access to biologic therapies and Janus kinase (JAK) inhibitors for patients with rheumatic musculoskeletal diseases (RMDs), while also reducing treatment costs.

The Top 5 Biosimilar Articles for the Week of January 22

January 26th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 22, 2024.

Eye on Pharma: Eylea Biosimilar Violation; New FDA Labeling Guidance; Alvotech Reinspection

January 25th 2024

By Skylar Jeremias

Article

A Korean health agency issued Samsung Bioepis an administrative penalty related to its biosimilar referencing Eylea (aflibercept); the FDA updates its labeling recommendations for interchangeable biosimilars; Alvotech receives another Form 483 after the FDA reinspected its Iceland-based manufacturing facility.

Bevacizumab Biosimilar MB02 Demonstrates Bioequivalence in Key Safety Parameters With Avastin

January 24th 2024

By Cameron Santoro

Article

A combined analysis of 3 studies found that the drug MB02 is comparable to reference bevacizumab (Avastin) in terms of its pharmacokinetics, safety, and immunogenicity.

Report: Varied Biosimilar Uptake Speeds Pose Missed Opportunities for Cost Savings

January 23rd 2024

By Skylar Jeremias

Article

Samsung Bioepis’ Biosimilar Market Report for the first quarter of 2024 chronicles some major market trends, including which treatment spaces have quicker uptake than others, highlighting missed opportunities for savings as well as the 1-year experience of adalimumab biosimilar competition in the US.

BioRationality: It Takes 4 to Tango—How US Entities Can Make Biosimilars Accessible

January 22nd 2024

By Sarfaraz K. Niazi, PhD

Article

The FDA, Congress, biologic developers, and associations dedicated to evaluating the US biopharmaceutical space will need to work together to overcome challenges to biosimilar accessibility, says Sarfaraz K. Niazi, PhD, in his new column.

Greater Biosimilar Uptake Found in Medicare Advantage Than Traditional Medicare

January 21st 2024

By Cameron Santoro

Article

Biosimilar uptake was greater in Medicare Advantage plans when compared with traditional Medicare plans.